CSPC Pharmaceutical Group (1093) Stock Price, Fundamentals & Analysis

What 1093 does

CSPC Pharmaceutical Group (1093) is an investment holding company that manufactures and sells pharmaceutical products across Mainland China, other Asian regions, Europe, North America, and internationally. It operates through three segments: Finished Drugs, Bulk Products, and Functional Food and Others. Its product portfolio includes NBP soft capsules and injections for acute ischemic stroke, Oulaining capsules and injections for mild to moderate memory and mental impairment, Enxi for adult idiopathic Parkinson's disease, Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors, Jinyouli to prevent infection induced by chemotherapy, and Keaili for breast cancer. The stock trades on the Hong Kong Stock Exchange in the Healthcare sector, specifically in the Drug Manufacturers - General industry.

Key numbers explained

• The current price is 9.33 HKD, with a -0.11% change today, reflecting the latest trading session movement.
• The trailing P/E ratio of 12.6 shows how much investors pay per unit of recent earnings; a lower figure can suggest relative affordability compared to peers like WuXi Biologics (2269).
• The forward P/E ratio of 14 uses expected future earnings, offering a look at how the market prices in growth.
• Earnings per share, trailing 12 months of 0.74 CNY represents the portion of profit attributable to each share over the last twelve months.
• The dividend yield of 3.86% indicates the annual dividend income as a percentage of the current share price, with 40% of earnings paid out as dividends.
• The ex-dividend date is 20 oct. 2026, the cutoff date for eligibility to receive the next dividend payment.
• Beta of 0.76 suggests the stock has historically been less volatile than the overall market.
• The debt-to-equity ratio of 1.7% measures financial leverage, showing the proportion of debt relative to shareholders' equity.

What to watch

Investors tracking CSPC Pharmaceutical Group (1093) often monitor its revenue growth, which has been 93.8% year over year, alongside its profitMargin of 23.7% and operatingMargin of 52.6%. The returnOnEquity of 20.9% indicates how efficiently the company generates profits from shareholders' equity. The priceToBook ratio of 2.41 compares the market value to the company's book value. The nextEarningsDate of 19 nov. 2026 is a key date for updated financial results. As a healthcare stock, it is influenced by regulatory changes, drug approval cycles, and broader sector trends, similar to other companies in the space such as Sino Biopharm (1177) and Hansoh Pharmaceutical Group (3692).